MUNICH, December 13, 2017 – Elekta (EKTA-B.ST) and Brainlab today announced an exclusive agreement in which Brainlab will become the authorized distributor of Elekta’s stereotactic solutions for neurosurgery in the United States.
Leksell Vantage™ Stereotactic System, which is included in the agreement, received CE Mark earlier this year and is already being adopted by European neurosurgeons. The Vantage system has received 510(k) clearance from the U.S. Food and Drug Administration and is available for sale in the U.S.
“Early adopters of the Vantage system are experiencing clinical and patient benefits from its multiple design innovations,” said Jesper Söderqvist, Vice President Neuro Portfolio at Elekta. “These include stereotactic magnetic resonance imaging with fewer restrictions, easier target coordinate setting during surgery as well as improved anesthetic capabilities.”
In September 2016, Elekta and Brainlab announced an agreement designed to ensure the continuous evolution of interoperability and safety of Leksell Vantage Stereotactic System and Elements Stereotaxy, a treatment planning and verification software from Brainlab. The integrated use of both systems is designed to assure safety in stereotactic neurosurgical procedures. In June 2017, the companies announced that Brainlab would be the authorized distributor of Elekta’s stereotactic solutions for neurosurgery, including Vantage, in selected markets in Europe.
“We strive to make medical technology more impactful and accessible to physicians and their patients,” commented Paolo Jelmoni, Vice President, Functional and Stereotactic Neurosurgery at Brainlab. “By partnering with Elekta, we are increasing our reach and providing clinicians with advanced and innovative technology on the stereotactic neurosurgery market.”
“Brainlab shares our vision for improving care and outcomes for patients undergoing neurosurgical procedures. The expanded partnership with Brainlab, with a large and specialized sales and service team, to distribute Vantage in the United States gives us a strong position from which to realize the potential of the system to advance the care of patients undergoing stereotactic neurosurgery procedures,” said Peter Gaccione, Executive Vice President, Elekta North America.
Stereotactic neurosurgery is a minimally invasive approach to precisely localize and treat specific regions in the brain while sparing surrounding healthy tissue. This surgery has been used successfully for decades to treat a variety of brain and neurologic conditions, including brain tumors, essential tremor and Parkinson’s disease. Stereotactic neurosurgery is often used to implant deep brain stimulation (DBS) leads or to perform lesioning of small brain targets for treating functional disorders. Immobilization of the patient’s head during neuroimaging and subsequent neurosurgical procedures is essential for accurate targeting and clinical safety and efficacy.
Brainlab develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments. Brainlab technology powers treatments in radiosurgery as well as numerous surgical fields including neurosurgery, orthopedic, ENT, CMF, spine and trauma. Founded in Munich in 1989, Brainlab has over 11,800 systems installed in over 100 countries. www.brainlab.com